Kyoto Drug Discovery & Development Co., Ltd.

Based in Japan, Kyoto Drug Discovery & Development Co. , Ltd. focuses on developing innovative therapeutic agents for treating retinal disorders, striving to improve patient outcomes through targeted ophthalmic solutions. Kyoto Drug Discovery & Development Co.

, Ltd. is engaged in the research and development of therapies for retinal disorders. Founded in 2015 in Osaka-shi, Japan, the company has executed a total of 4 deals, with its most recent deal occurring on July 31, 2019. In this round, the company raised JPY 400 million from investors including SBI Investment and Kyoto University Innovation Capital.

The total amount raised by the company stands at JPY 400 million. Kyoto Drug Discovery & Development Co. , Ltd. specializes in the development of innovative therapeutic agents aimed at treating retinal disorders, including central retinal artery occlusion, retinitis pigmentosa, and glaucoma.

The company’s core offerings are designed to address significant unmet medical needs in ophthalmology, targeting the underlying mechanisms of these diseases to improve patient outcomes. The primary end users of these treatments include healthcare providers, such as ophthalmologists and clinics, as well as patients suffering from these debilitating conditions. While specific product release dates are not disclosed, the company is actively engaged in the research and development phase, indicating a focus on bringing these novel therapies to market in various geographical regions, including Japan, North America, and Europe. Kyoto Drug Discovery & Development Co.

, Ltd. generates revenue primarily through partnerships with healthcare providers and research institutions, as well as potential future collaborations with pharmaceutical companies for the commercialization of their therapeutic products. The transaction structure may involve direct sales to hospitals and clinics or agreements that allow for the distribution of their treatments through established pharmaceutical networks. Revenue generation is likely to be derived from a combination of upfront payments, royalties, and milestone payments tied to the successful development and commercialization of their therapies.

This strategic approach positions the company to establish a sustainable revenue model as it advances its product offerings through clinical trials and regulatory approvals. In July 2019, Kyoto Drug Discovery & Development Co. , Ltd. raised JPY 400 million in venture funding to support the development of new therapeutic products for retinal disorders.

The company is focused on expanding its market reach into North America and Europe by 2025, with ongoing efforts to advance its research and development activities. The recent funding will be utilized to enhance product development initiatives and facilitate entry into these new markets.